Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

0.0%

0 terminated out of 46 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

20%

9 trials in Phase 3/4

Results Transparency

50%

4 of 8 completed with results

Key Signals

4 with results100% success

Data Visualizations

Phase Distribution

38Total
Not Applicable (4)
P 1 (8)
P 2 (17)
P 3 (9)

Trial Status

Recruiting19
Not Yet Recruiting10
Completed8
Active Not Recruiting5
Enrolling By Invitation3
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (46)

Showing 20 of 20 trials
NCT07567716Enrolling By InvitationPrimary

Infiltration Pattern of Locally Advanced ESCC

NCT07559045Phase 2RecruitingPrimary

Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT07205731Phase 2RecruitingPrimary

Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

NCT07463573Phase 3RecruitingPrimary

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

NCT07085091Phase 1Recruiting

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

NCT03957590Phase 3CompletedPrimary

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

NCT07189871Phase 1Recruiting

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

NCT07481058Phase 2RecruitingPrimary

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

NCT07039162Phase 2RecruitingPrimary

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

NCT07403435Phase 2Not Yet RecruitingPrimary

Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC

NCT06952621Phase 3Not Yet RecruitingPrimary

Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma

NCT07376876Phase 2Not Yet RecruitingPrimary

Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy

NCT07359417Phase 1RecruitingPrimary

MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma

NCT07353541Not Yet RecruitingPrimary

Standardized Management of Esophageal Fistula in Esophageal Squamous Cell Carcinoma

NCT07339488Phase 2Active Not Recruiting

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

NCT07317609Phase 1RecruitingPrimary

Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)

NCT07290010Phase 2RecruitingPrimary

The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma

NCT05342636Phase 1CompletedPrimary

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

NCT07272291Phase 2Not Yet RecruitingPrimary

A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma

NCT07224750Recruiting

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

Scroll to load more

Research Network

Activity Timeline